← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Fudan oral prednisone acute tinnitus studies
Also known as: Prednisone Tablet, STOP-AST prednisone regimen studies
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Not applicable
Status
Completed
Target Gene
—
Route / Mode
Oral
Confidence
87%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
China
Population
adult, tinnitus
Trial IDs
2
Mechanism
Academic trials of short-term oral prednisone regimens, with ginkgo biloba co-therapy/comparator, for acute subjective tinnitus.
Indications
Notes
Registry-verified Fudan acute tinnitus prednisone study cluster. This is a generic academic steroid regimen study, not a current company-sponsored therapeutic program.
Evidence & Sources
2 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT06124703
clinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT05591144
Key Events
Clinical Trials (2)
Data Checks
institution-led-studyregistry-only-evidencegeneric-drug-study-clustermerged-generated-intervention-armsnot-confirmed-current-product
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2